7:01 am ET on Tuesday

For Immediate Release - 7:01 am ET on Tuesday, May 13, 2025

Acurx Pharmaceuticals, Inc. Reports First Quarter Results

and Provides Business Update

Staten Island, NY, May 13, 2025 -

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company

developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results

for the first quarter ended March 31, 2025.

Highlights of the first quarter ended March 31, 2025, or in some cases

shortly thereafter, include:

First Quarter 2025 Financial Results

The Company ended the quarter with

cash totaling $4.6 million, compared to $3.7 million as of December 31, 2024. The Company raised a total of approximately $3.6 million

of gross proceeds thru two Registered Direct Offerings.

Research and development expenses for

the three months ended March 31, 2025 were $0.6 million compared to $1.6 million for the three months ended March 31, 2024, a decrease

of $1.0 million. The decrease was due primarily to a decrease in manufacturing costs of $0.4 million, and a decrease in consulting costs

of $0.6 million as a result of the prior year trial related expenses.

General and administrative expenses

for the three months ended March 31, 2025 were $1.6 million compared to $2.8 million for the three months ended March 31, 2024, a decrease

of $1.2 million. The decrease was primarily due to $0.7 million decrease in professional fees resulting from lower consulting expenses,

and a $0.6 million decrease in share-based compensation costs.

The Company reported a net loss of $2.1

million or $0.11 per diluted share for the three months ended March 31, 2025 compared to a net loss of $4.4 million or $0.28 per diluted

share for the three months ended March 31, 2024, for the reasons previously mentioned.

The Company had 22,397,511 shares outstanding as of March 31, 2025.

As previously announced, David P. Luci,

President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results

and provide a business update as follows:

the Company's lead antibiotic candidate advancing to international Phase 3 clinical trials to treat patients with C. difficile

Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS )

antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.

Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria

phyla, appears to contribute to the maintenance of a healthy gut microbiome. In June 2018, ibezapolstat was designated by the U.S. Food

and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible

to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN)

Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has

designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a late-stage

biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections.

The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS ) that blocks the active

site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial

cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile,

methicillinresistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae

To learn more about Acurx Pharmaceuticals

and its product pipeline, please visit www.acurxpharma.com.

Forward-Looking Statements

Any statements in this press

release about our future expectations, plans and prospects, including statements regarding our strategy, future operations,

prospects, plans and objectives, and other statements containing the words "believes," "anticipates,"

"plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The

Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking

statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether

ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of

ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive

approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval,

it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed

with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent

filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press

release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances

after the date of such statements, except as may be required by law.

Acurx Pharmaceuticals, Inc.

David P. Luci, President & Chief Executive Officer

Email: davidluci@acurxpharma.com

Source: Acurx Pharmaceuticals, Inc.

ACURX PHARMACEUTICALS,

CONDENSED INTERIM BALANCE SHEETS

ACURX PHARMACEUTICALS, INC.

CONDENSED INTERIM STATEMENTS OF OPERATIONS